PathAI Partners with Discovery Life Sciences to Deploy First AI-Powered Biospecimen Solutions

Collaboration Marks First At-Scale Deployment of AI Technologies into Leading Commercial Biobank

PathAI, a leading provider of AI-powered technology for pathology, today announced a strategic partnership with Discovery Life Sciences, a leading biospecimens and specialty lab testing company, to offer Discovery’s customers enhanced, AI-enabled digital and quantitative insights from biospecimens to better inform drug and diagnostic development. This collaboration marks a milestone as the first at-scale deployment of AI technologies into a leading commercial biobank.

Also Read: Role of AI in Cybersecurity: Protecting Digital Assets From Cybercrime

Through this partnership, Discovery will deploy PathAI’s AISight Image Management System (IMS), ArtifactDetect, and TumorDetect products globally across its biospecimens business. In doing so, Discovery will help transform their traditional pathology workflow, significantly saving pathologists’ time by automating routine tasks and analysis and allowing pathologists to focus on more complex tasks. Discovery will also empower customers with additional quantitative, tissue-level insights to provide more confident and standardized structured data from their biospecimens.

Building on this deployment, the companies will collaborate to develop a custom AI-driven tissue analysis panel exclusive to Discovery, further advancing translational research and biomarker discovery for biopharma partners. Looking beyond applications within Discovery’s biospecimens business, this partnership will allow for further exploration within Discovery’s Specialty Lab Services business, leveraging AI-driven solutions to deliver deeper insights to accelerate drug development and precision medicine initiatives.

Also Read: AI and Social Media: What Should Social Media Users Understand About Algorithms?

“We are excited to partner with Discovery Life Sciences to revolutionize the biospecimens industry,” said Andy Beck, CEO of PathAI. “Our digital pathology solutions will enable Discovery Life Sciences to provide unparalleled accuracy and speed in pathology assessments, ultimately benefiting their customers with enhanced data quality and insights and accelerating the discovery and development of new therapies and diagnostics.”

“Integrating PathAI’s advanced AI technology aligns perfectly with our commitment to providing our customers with the highest quality and most comprehensive data and insights from their biospecimens investment,” said Greg Herrema, CEO of Discovery. “This partnership will significantly enhance our ability to deliver precise, reliable, and timely insights, ultimately advancing the discovery and development of therapies and diagnostics that improve patient outcomes.”

As investments in immuno-oncology and antibody-drug conjugates continue to rise, the need for precision diagnostic tools that optimize patient selection will become more critical. The combination of PathAI’s products and Discovery’s high-quality, structured, multi-modal datasets will catalyze the development of new assays and diagnostic tools more reliably and quickly with the objective of enabling improved patient outcomes.

[To share your insights with us as part of editorial or sponsored content, please write to psen@itechseries.com]